SOST and osteoporosis: Therefore, the inhibition of sclerostin was proposed as a therapeutic approach in the treatment of bone loss [349], which led to the development and approval in the US and Europe of the monoclonal sclerostin-antibody Romosozumab for severe osteoporosis [350,351,352,353].